Drugs / LianHuaQingWen Granules
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05366231 Comparator | May → Sep 2022 | pneumonia | Guizhou Bailing Group Pharmaceutical Co Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LianHuaQingWen Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366231 ↗ |
| Route | Oral | “LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day” NCT05366231 ↗ |